Clinical impact of the worldwide shortage of verteporfin (Visudyne (R)) on ophthalmic care

Sirks, M.J.; Dijk, E.H.C. van; Rosenberg, N.; Hollak, C.E.M.; Aslanis, S.; Cheung, C.M.G.; ... ; Schlingemann, R.O. (2022)

Article / Letter to editor

Introduction: Since July 2021, a worldwide shortage of verteporfin (Visudyne (R)) occurred: an essential medicine required for photodynamic therapy (PDT). PDT with verteporfin has a broad range of indications in ophthalmology, including chronic central serous chorioretinopathy, polypoidal choroidal vasculopathy and choroidal haemangioma. For these disorders, PDT is either the first-choice treatment or regarded as a major treatment option. Materials and methods: A questionnaire was sent to key opinion leaders in the field of medical retina throughout the world, to assess the role of PDT in their country and the effects of the shortage of verteporfin. In addition, information on the application of alternative treatments during shortage of verteporfin was obtained, to further assess the impact of the shortage. Results: Our questionnaire indicated that the shortage of verteporfin had a major impact on ophthalmic care worldwide and was regarded to be a serious problem by most of our respondents. However, even though there is ample evidence to support the use of PDT in several chorioretinal diseases, we found notable differences in its use in normal patient care throughout the world. Various alternative management strategies were noted during the verteporfin shortage, including lowering the dose of verteporfin per patient, the use of alternative treatment strategies and the use of a centralized system for allocating the remaining ampoules of verteporfin in some countries. Conclusion: The shortage of verteporfin has had a large effect on the care of ophthalmic patients across the world and may have resulted in significant and irreversible vision loss. Mitigation strategies should be developed in consultation with all stakeholders to avoid future medication shortages of verteporfin and other unique ophthalmic medications. These strategies may include mandatory stock keeping, compulsory licensing to an alternative manufacturer or incentivizing the development of competition, for example through novel public-private partnerships.

• age-related macular degeneration
• central serous chorioretinopathy
• choroidal haemangioma
• photodynamic therapy
• polypoidal choroidal vasculopathy
• verteporfin

• All authors: Sirks, M.J.; Dijk, E.H.C. van; Rosenberg, N.; Hollak, C.E.M.; Aslanis, S.; Cheung, C.M.G.; Chowers, I.; Eandi, C.M.; Freund, K.B.; Holz, F.G.; Kaiser, P.K.; Lotery, A.J.; Ohno-Matsui, K.; Querques, G.; Subhi, Y.; Tadayoni, R.; Wykoff, C.C.; D. zur; Diederen, R.M.H.; Boon, C.J.F.; Schlingemann, R.O.
• Date: 2022-04-06
• Journal: Acta Ophthalmologica
• Volume: 100
• Issue: 7
• Pages: E1522 - E1532
• DOI: doi:10.1111/aos.15148